Long-term drug treatment of unipolar depression

International Clinical Psychopharmacology

Volumn 11, Issue 4, 1996, Pages 211-217

  Hirschfeld, R M A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

maintenance therapy; prophylaxis; recurrence; relapse; unipolar depression

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

AGE; CARDIOTOXICITY; CONSTIPATION; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0030463806     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199612000-00001     Document Type: Review

References (45)

1. Angst J (1992) How recurrent and predictable is depressive illness? In: Perspectives in Psychiatry (Eds S Montgomery and F Rouillon). Vol. 3, pp.1-13 Wiley, Chichester.
2. Anonymous (1992) Depression and suicide: are they preventable? Lancet, 340, 700-701.
3. Bjork K (1983) The efficacy of zimelidine in preventing depressive episodes in recurrent major depressive disorders: a double-blind placebo-controlled study. Acta Psychiatrica Scandinavica, 68, 182-189.
4. Burrows GD (1992) Long-term clinical management of depressive disorders. Journal of Clinical Psychiatry, 53 (3, Suppl), 32-35.
5. Cassidy S and Henry J (1987) Fatal toxicity of antidepressant drugs in overdose, British Medical Journal, 295, 1021-1024.
6. Claghorn JL (1991) Paroxetine: long-term efficacy and tolerability. Presented at the 5th World Congress of Biological Psychiatry, Florence.
7. Claghorn JL and Feighner JP (1993) A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. Journal of Clinical Psychopharmacology, 13 (Suppl 2), 23S-33S.
8. Coppen A, Ghose K, Montgomery S et al. (1978) Continuation therapy with amitriptyline in depression. British Journal of Psychiatry, 133, 28-33.
9. Davis JM, Wang Z and Janicak PJ (1993) A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacology Bulletin, 29, 175-181.
10. Doogan DP and Caillard V (1988) Sertraline: a new antidepressant. Journal of Clinical Psychiatry, 49 (Suppl 8), 46-51.
11. Doogan DP and Caillard V (1992) Sertraline in the prevention of depression. British Journal of Psychiatry, 160, 217-222.
12. Duboff EA (1993) Long-term treatment of major depressive disorder with paroxetine. Journal of Clinical Psychopharmacology, Suppl 2, 28S-33S.
13. Frank E, Kupfer DJ, Perel JM et al. (1990) Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093-1099.
14. Frank E, Kupfer DJ, Perel JM et al. (1993) Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. Journal of Affective Disorders, 27, 139-145.
15. Georgotas A, McCue RE and Cooper TB (1989) A placebo-controlled comparison of nortriptyline and phenelzine in elderly depressed patients. Archives of General Psychiatry, 46, 783-786.
16. Glen AIM, Johnson AL and Shepherd M (1984) Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind controlled trial. Psychological Medicine, 14, 37-50.
17. Greenberg PE, Stiglin LE, Finkelstein SN et al. (1993) The economic burden of depression in 1990. Journal of Clinical Psychiatry, 54, 405-418.
18. Hirschfeld RM and Schatzberg AF (1994) Long-term management of depression. American Journal of Medicine, 97, 33S-38S.
19. Janicak PG, Davis JM, Preskorn SH et al. (1993) Treatment with antidepressants. In: Principles and Practice of Psychopharmacotherapy, pp.209-292. Williams & Wilkins, Baltimore.
20. Jenner PN (1992) Paroxetine: an overview of dosage, tolerability and safety. International Clinical Psychopharmacology, 6 (Suppl 4), 69-80.
21. Kane JM, Quitkin FM, Rifkin A et al. (1982) Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness. Archives of General Psychiatry, 39, 1065-1069.
22. Keller MB (1990) Depression. Underrecognition and undertreatment by psychiatrists and other health care professionals. Archives of Internal Medicine, 150, 946-948.
23. Kupfer DJ (1991) Long-term management of depression. Journal of Clinical Psychiatry, 52 (Suppl 5), 28-34.
24. Kupfer DJ, Frank E, Perel JM et al. (1992) Five-year outcome for maintenance therapies in recurrent depression. Archives of General Psychiatry, 49, 769-773.
25. Montgomery SA (1989) Prophylaxis in recurrent unipolar depression: a new indication for treatment studies. Journal of Psychopharmacology, 3 (Suppl 2), 47-53.
26. Montgomery S and Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International Clinical Psychopharmacology, 8, 189-195.
27. Montgomery SA and Montgomery DB (1992) Prophylactic treatment in recurrent depression. In: Perspectives in Psychiatry (Eds S Montgomery and F Rouillon), Vol. 3, pp. 53-79. Wiley, Chichester.
28. Montgomery SA, Dufour H, Brion S et al. (1988) The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry, 3, 69-76.
29. Montgomery SA, Doogan DP and Burnside R (1991) The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. International Clinical Psychopharmacology, 6 (Suppl 2), 37-46.
30. NIMH/NIH Consensus Development Panel (1985) Mood disorders: pharmacologic prevention of recurrences. American Journal of Psychiatry, 142, 469-476.
31. Pérez-Stable EJ, Miranda J, Muñoz RF et al. (1990) Depression in medical outpatients. Underrecognition and misdiagnosis. Archives of Internal Medicine, 150, 1083-1088.
32. Prien RF and Kupfer DJ (1986) Continuation drug therapy for major depressive episodes: how long should it be maintained? American Journal of Psychiatry, 143, 18-23.
33. Prien RF, Klett CJ and Caffey EM (1973) Lithium carbonate and imipramine in the prevention of affective episodes. Archives of General Psychiatry, 29, 420-425.
34. Prien RF, Kupfer DJ, Mansky PA et al. (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Archives of General Psychiatry, 41, 1096-1104.
35. Priest RG (1994) Improving the management and knowledge of depression. Marking "Defeat Depression Action Week" for the Defeat Depression Campaign. British Journal of Psychiatry, 164, 285-287.
36. Regier DA, Hirschfeld RMA, Goodwin FK, Burke JD Jr, Lazar JB and Judd LL (1988) The NIMH Depression Awareness, Recognition and Treatment program: structure, aims and scientific basis. American Journal of Psychiatry, 145, 1351-1357.
37. Reynolds JEF, Parfitt K, Parsons A and Sweetman SC (Eds) (1993) Martindale's Extra Pharmacopoeia, 30th edn, p.269. Pharmaceutical Press, London.
38. Robinson DS, Lerfald SC, Bennet B et al. (1991) Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacology Bulletin, 27, 31-38.
39. Rouillon F, Phillips R, Serrurier D et al. (1989) Rechutes de dépression unipolaire et efficacité de la maprotiline. L'Encéphale, 15, 527-534.
40. Rouillon F, Lejoyeux M and Filteau MJ (1992) Unwanted effects of long-term treatment. In: Perspectives in Psychiatry (Eds S Montgomery and F Rouillon), Vol.3, pp.81-111. Wiley, Chichester.
41. Solomon DA and Bauer MS (1993) Continuation and maintenance pharmacotherapy for unipolar and bipolar mood disorders. Psychiatric Clinics of North America, 16, 515-540.
42. Stein MK, Rickels K and Weise CI (1980) Maintenance therapy with amitriptyline: a controlled trial. American Journal of Psychiatry, 137, 370-371.
43. Thase ME (1992) Long-term treatments of recurrent depressive disorders. Journal of Clinical Psychiatry, 53 (Suppl 9), 32-44.
44. Wells KB, Stewart A, Hays RD et al. (1989) The functioning and well-being of depressed patients. Results from the medical outcomes study. Journal of the American Medical Association, 262, 914-919.
45. WHO Mental Health Collaborating Centres (1989) Pharmacotherapy of depressive disorders: a consensus statement. Journal of Affective Disorders, 17, 197-198.